Senti Biosciences (SNTI) said Monday that the first patient has been dosed in the pilot trial of SN301A to treat hepatocellular carcinoma.
The biotech firm said the trial, which is taking place in mainland China, is part of a collaboration with Celest Therapeutics.
Senti Bio said the two companies have the option to expand clinical development of SN301A to Hong Kong, Macau and Taiwan. It also said it will maintain all development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan.
Price: 5.21, Change: -0.36, Percent Change: -6.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments